<?xml version="1.0" encoding="UTF-8"?>
<p id="p0245">Zhou et al. proposed that hydroxychloroquine could serve as a better therapeutic agent than chloroquine, owing to reduced toxicity, fewer side-effects, lower cost, and relative safety in pregnancy.
 <xref rid="bib47" ref-type="bibr">
  <sup>47</sup>
 </xref> Yao et al. used physiologically based pharmacokinetics models and found that hydroxychloroquine was more potent than chloroquine at inhibiting SARS-CoV-2 
 <italic>in vitro</italic>. They recommended 400 mg hydroxychloroquine sulfate twice daily for 1 day, followed by 200 mg twice daily for 4 days to treat SARS-CoV-2 infection.
 <xref rid="bib48" ref-type="bibr">
  <sup>48</sup>
 </xref> The efficacy and safety data of chloroquine or hydroxychloroquine from high-quality clinical trials are urgently needed.
</p>
